Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
bioAffinity Technologies Inc. Warrant (BIAFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: BIAFW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 32.75% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.56 | 52 Weeks Range 0.10 - 2.90 | Updated Date 06/14/2025 |
52 Weeks Range 0.10 - 2.90 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -110.55% | Operating Margin (TTM) -141.73% |
Management Effectiveness
Return on Assets (TTM) -88.58% | Return on Equity (TTM) -290.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 21528674 |
Shares Outstanding - | Shares Floating 21528674 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
bioAffinity Technologies Inc. Warrant
Company Overview
History and Background
bioAffinity Technologies, Inc. is a cancer diagnostics company focusing on early cancer detection and cancer therapeutics. It was founded in 2014. The company develops non-invasive diagnostics and targeted therapies to address significant unmet needs in the treatment of cancer and other diseases.
Core Business Areas
- Diagnostics: Development and commercialization of CyPathu00ae Lung, a non-invasive test for early lung cancer detection, and other diagnostics for various types of cancer.
- Therapeutics: Research and development of therapeutic compounds for cancer treatment, including targeted therapies.
Leadership and Structure
Maria Zannes is the President and CEO. The company operates with a board of directors and a management team overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: A non-invasive sputum-based test for early lung cancer detection. Market share is still growing as the company is in early commercialization. Competitors include companies providing liquid biopsy tests like Guardant Health (GH) and Exact Sciences (EXAS) as well as other traditional diagnostic methods. Revenue is not yet significant as of 2023 SEC fillings.
Market Dynamics
Industry Overview
The cancer diagnostics industry is experiencing significant growth, driven by advancements in genomics, proteomics, and imaging technologies. Early cancer detection is a major focus, with increasing demand for non-invasive and accurate diagnostic tools.
Positioning
bioAffinity Technologies is positioning itself as a leader in non-invasive early cancer detection. Its competitive advantage lies in the unique porphyrin-based technology platform.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is estimated to be billions of dollars. bioAffinity Technologies is positioned to capture a portion of this market with its CyPathu00ae Lung test.
Upturn SWOT Analysis
Strengths
- Non-invasive diagnostic technology
- Potential for early cancer detection
- Proprietary porphyrin-based platform
- Experienced management team
Weaknesses
- Limited commercialization history
- Dependence on a single product (CyPathu00ae Lung)
- High cash burn rate
- Need for regulatory approvals
Opportunities
- Expanding into other cancer diagnostics
- Partnering with pharmaceutical companies
- Securing regulatory approvals
- Increasing market awareness
Threats
- Competition from established diagnostic companies
- Technological advancements by competitors
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- GH
- EXAS
- CGDX
Competitive Landscape
bioAffinity Technologies faces competition from larger, established companies with greater resources. The company's innovative technology could provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to early stage of commercialization.
Future Projections: Projected revenue growth is based on the successful commercialization of CyPathu00ae Lung and expansion into other cancer diagnostics.
Recent Initiatives: Focus on securing regulatory approvals, expanding sales and marketing efforts, and developing new diagnostic products.
Summary
bioAffinity Technologies Inc. is a high-risk, high-reward company focused on early cancer detection. Its proprietary technology offers promise, but the company faces significant challenges in commercialization and competition. Success hinges on securing regulatory approvals, expanding sales, and raising additional capital. The warrant trades based on potential exercise into a positive situation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings, Company Website, Analyst Reports (where available - limited availability for warrant directly)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies Inc. Warrant
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.